Botulinum Toxin Type A and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine
Authors:
- 11 December 2007
- journal article
- clinical trial
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 48 (2) , 210-220
Abstract
Objective.— To compare the efficacy and safety of botulinum toxin type A (BoNTA; BOTOX®: Allergan, Inc.) and divalproex sodium (DVPX; DEPAKOTE®: Abbott Laboratories) as prophylaxis in reducing disability and impact associated with migraine.Background.— There is a need for effective, well‐tolerated prophylactic treatment of migraine.Design/Methods.— This was a randomized, double‐blind, single‐center prospective study. Fifty‐nine patients received either BoNTA 100 U/placebo‐DVPX bid or placebo‐BoNTA/DVPX 250 mg bid. BoNTA/placebo injections were given at Day 0 and at Month 3. Patients were evaluated at Months 1, 3, 6, and 9.Results.— Both treatments showed significant improvements in migraine disability scores and reductions in headache days and headache index. A trend to decreased headache severity was observed with BoNTA. A greater percentage of DVPX patients reported adverse events possibly related to treatment (DVPX 75.8% vs BoNTA 50%, P = .04) and discontinued because of adverse events (DVPX 27.6% vs BoNTA 3.3%, P = .012).Conclusions.— Both BoNTA and DVPX significantly reduced disability associated with migraine; BoNTA had a favorable tolerability profile compared with DVPX.Keywords
This publication has 35 references indexed in Scilit:
- A Double-Blind, Randomized, Placebo-Controlled Comparison of Botulinum Toxin Type A Injection Sites and Doses in the Prevention of Episodic MigrainePain Medicine, 2007
- A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Multiple Treatments of Botulinum Toxin Type A (BoNTA) for the Prophylaxis of Episodic Migraine HeadachesCephalalgia, 2007
- Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled StudyHeadache: The Journal of Head and Face Pain, 2005
- Botulinum Toxin Type A (BOTOX ® ) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled TrialHeadache: The Journal of Head and Face Pain, 2005
- Botulinum Toxin A in the Prophylactic Treatment of Migraine – A Randomized, Double-Blind, Placebo-Controlled StudyCephalalgia, 2004
- The Burden of Migraine in SpainPharmacoEconomics, 2004
- Economic Impact of Migraine and Other Episodic Headaches in FrancePharmacoEconomics, 2004
- Efficacy and Tolerability in Migraine Prophylaxis of Flunarizine in Reduced Doses: A Comparison with Propranolol 160 Mg DailyCephalalgia, 2002
- Validation of a New Quality of Life Questionnaire for Acute Migraine HeadacheHeadache: The Journal of Head and Face Pain, 1995
- Placebo Effect and Clinical Trials in Migraine TherapyNeuroepidemiology, 1987